Henry Uhlman Bryant

TL;DR: The current understanding of the Wnt signaling pathway in terms of bone biology is discussed and whether targeting this pathway might yield novel therapeutics to treat typical bone disorders is assessed.

TL;DR: Structural differences between raloxifene and tamoxifen may influence the conformations of their respective receptor/ligand complexes, thereby affecting which estrogen-responsive genes are modulated in various tissues, indicating that differences in tissue selective actions among benzothiophene and triarylethylene estrogen receptor modulators can be ascribed to discrete ligand conformations.

TL;DR: The effect of a small molecule GSK‐3 inhibitor was evaluated in pre‐osteoblasts and in osteopenic rats with concomitant increased bone mass and strength in rats.

TL;DR: It is clear that for raloxifene, both the estrogen agonist effects on bone and cholesterol metabolism as well as the estrogen antagonist effects in uterine and mammary tissue involve high affinity interaction with the estrogen receptor.

TL;DR: 4c is identified as a novel SERM with greater potency to antagonize estrogen in uterine tissue and in human mammary cancer cells compared to raloxifene, tamoxifen or ICI-182,780.